CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
105.23
0.56%
Market Trading Hours* (UTC) Opens on Friday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.11
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Abbott Laboratories ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 105.81
Open* 106.33
1-Year Change* 1.84%
Day's Range* 104.47 - 106.33
52 wk Range 89.67-115.83
Average Volume (10 days) 4.76M
Average Volume (3 months) 113.73M
Market Cap 197.95B
P/E Ratio 38.67
Shares Outstanding 1.74B
Revenue 39.96B
EPS 2.95
Dividend (Yield %) 1.92949
Beta 0.74
Next Earnings Date Jan 24, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 18, 2024 105.22 -0.40 -0.38% 105.62 106.93 104.41
Apr 17, 2024 105.81 -1.65 -1.54% 107.46 107.85 104.12
Apr 16, 2024 108.88 0.07 0.06% 108.81 110.28 108.04
Apr 15, 2024 108.82 -0.77 -0.70% 109.59 110.80 108.76
Apr 12, 2024 109.01 -0.60 -0.55% 109.61 110.42 108.42
Apr 11, 2024 111.34 0.18 0.16% 111.16 111.72 110.23
Apr 10, 2024 111.09 0.43 0.39% 110.66 111.42 110.29
Apr 9, 2024 112.37 1.84 1.66% 110.53 112.51 110.44
Apr 8, 2024 110.49 -0.57 -0.51% 111.06 111.32 110.08
Apr 5, 2024 111.17 2.10 1.93% 109.07 111.20 109.05
Apr 4, 2024 110.03 -1.47 -1.32% 111.50 111.90 109.75
Apr 3, 2024 111.21 -0.66 -0.59% 111.87 112.44 110.96
Apr 2, 2024 111.97 0.32 0.29% 111.65 112.37 111.05
Apr 1, 2024 112.00 -1.43 -1.26% 113.43 113.53 111.75
Mar 28, 2024 113.49 0.37 0.33% 113.12 113.96 112.80
Mar 27, 2024 113.41 1.65 1.48% 111.76 113.64 110.34
Mar 26, 2024 111.45 1.40 1.27% 110.05 111.82 109.72
Mar 25, 2024 109.94 -0.36 -0.33% 110.30 110.56 109.06
Mar 22, 2024 110.49 -0.96 -0.86% 111.45 111.90 110.47
Mar 21, 2024 111.37 -0.43 -0.38% 111.80 112.07 110.95

Abbott Laboratories Events

Time (UTC) Country Event
Friday, April 26, 2024

Time (UTC)

14:00

Country

US

Event

Abbott Laboratories Annual Shareholders Meeting
Abbott Laboratories Annual Shareholders Meeting

Forecast

-

Previous

-

Time (UTC)

14:00

Country

US

Event

Abbott Laboratories Annual Shareholders Meeting
Abbott Laboratories Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, July 18, 2024

Time (UTC)

12:30

Country

US

Event

Q2 2024 Abbott Laboratories Earnings Release
Q2 2024 Abbott Laboratories Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 43653 43075 34608 31904 30578
Revenue 43653 43075 34608 31904 30578
Cost of Revenue, Total 19083 18490 14967 13196 12691
Gross Profit 24570 24585 19641 18708 17887
Total Operating Expense 35336 34650 29136 27435 27095
Selling/General/Admin. Expenses, Total 11109 11217 9676 9694 9691
Research & Development 2741 2733 2403 2408 2288
Depreciation / Amortization 2013 2047 2132 1936 2178
Unusual Expense (Income) 390 163 -42 201 247
Operating Income 8317 8425 5472 4469 3483
Interest Income (Expense), Net Non-Operating -377 -491 -492 -583 -749
Other, Net 366 277 -12 191 139
Net Income Before Taxes 8306 8211 4968 4077 2873
Net Income After Taxes 6933 7071 4497 3601 2464
Net Income Before Extra. Items 6933 7071 4497 3601 2464
Total Extraordinary Items 0 -2 86 -96
Net Income 6933 7071 4495 3687 2368
Income Available to Common Excl. Extra. Items 6933 7071 4497 3601 2464
Income Available to Common Incl. Extra. Items 6933 7071 4495 3687 2368
Diluted Net Income 6933 7071 4495 3687 2368
Diluted Weighted Average Shares 1764 1789 1786 1781 1770
Diluted EPS Excluding Extraordinary Items 3.93027 3.95249 2.51792 2.0219 1.39209
Dividends per Share - Common Stock Primary Issue 1.88 1.8 1.44 1.28 1.12
Diluted Normalized EPS 4.11623 4.03095 2.49663 2.12158 1.51177
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 10143 9978 9747 10091 10410
Revenue 10143 9978 9747 10091 10410
Cost of Revenue, Total 4605 4483 4325 4593 4629
Gross Profit 5538 5495 5422 5498 5781
Total Operating Expense 8473 8436 8238 8787 8640
Selling/General/Admin. Expenses, Total 2680 2740 2751 2973 2731
Research & Development 626 715 654 725 671
Depreciation / Amortization 496 498 491 496 498
Unusual Expense (Income) 66 17 0 111
Operating Income 1670 1542 1509 1304 1770
Interest Income (Expense), Net Non-Operating -59 -82 -58 -52 -105
Other, Net 60 176 111 68 93
Net Income Before Taxes 1671 1636 1562 1320 1758
Net Income After Taxes 1436 1375 1318 1033 1435
Net Income Before Extra. Items 1436 1375 1318 1033 1435
Total Extraordinary Items
Net Income 1436 1375 1318 1033 1435
Income Available to Common Excl. Extra. Items 1436 1375 1318 1033 1435
Income Available to Common Incl. Extra. Items 1436 1375 1318 1033 1435
Diluted Net Income 1436 1375 1318 1033 1435
Diluted Weighted Average Shares 1748 1750.25 1751.71 1752.46 1763.65
Diluted EPS Excluding Extraordinary Items 0.82151 0.7856 0.75241 0.58946 0.81365
Dividends per Share - Common Stock Primary Issue 0.51 0.51 0.51 0.47 0.47
Diluted Normalized EPS 0.87657 0.7856 0.76059 0.58946 0.86503
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 25224 24239 20441 15667 14632
Cash and Short Term Investments 10170 10249 7148 4140 4086
Cash & Equivalents 9882 9799 6838 3860 3844
Short Term Investments 288 450 310 280 242
Total Receivables, Net 6218 6487 6414 5425 5182
Accounts Receivable - Trade, Net 6218 6487 6414 5425 5182
Total Inventory 6173 5157 5012 4316 3796
Prepaid Expenses 2663 2346 1867 1638 1445
Other Current Assets, Total 148 123
Total Assets 74438 75196 72548 67887 67173
Property/Plant/Equipment, Total - Net 10278 10112 10130 8972 7563
Property/Plant/Equipment, Total - Gross 21328 20517 19894 17733 15706
Accumulated Depreciation, Total -11050 -10405 -9764 -8761 -8143
Goodwill, Net 22799 23231 23744 23195 23254
Intangibles, Net 10454 12739 14784 17025 18942
Long Term Investments 766 816 821 883 897
Other Long Term Assets, Total 4917 4059 2628 2145 1885
Total Current Liabilities 15489 13105 11907 10863 9012
Accounts Payable 4607 4408 3946 3252 2975
Accrued Expenses 7401 6806 6581 5183 4867
Notes Payable/Short Term Debt 0 0 213 201 200
Current Port. of LT Debt/Capital Leases 2251 754 7 1277 7
Other Current Liabilities, Total 1230 1137 1160 950 963
Total Liabilities 37752 39394 39764 36799 36649
Total Long Term Debt 14522 17296 18527 16115 19359
Long Term Debt 14522 17296 18527 16115 19359
Deferred Income Tax 991 1392 1406 1546 2056
Minority Interest 219 222 219 213 198
Other Liabilities, Total 6531 7379 7705 8062 6024
Total Equity 36686 35802 32784 31088 30524
Common Stock 24709 24470 24145 23853 23512
Retained Earnings (Accumulated Deficit) 35257 31528 27627 25847 24560
Treasury Stock - Common -15229 -11822 -10042 -10147 -9962
Unrealized Gain (Loss) 0 0
Other Equity, Total -8051 -8374 -8946 -8465 -7586
Total Liabilities & Shareholders’ Equity 74438 75196 72548 67887 67173
Total Common Shares Outstanding 1737.8 1764.08 1771.23 1762.5 1755.62
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 22664 23505 24377 25224 24845
Cash and Short Term Investments 7047 8155 9532 10170 9907
Cash & Equivalents 6709 7835 9161 9882 9594
Short Term Investments 338 320 371 288 313
Total Receivables, Net 6499 6172 6020 6218 6408
Accounts Receivable - Trade, Net 6499 6172 6020 6218 6408
Total Inventory 6650 6871 6673 6173 5734
Prepaid Expenses 2468 2307 2152 2663 2796
Total Assets 72090 73354 73794 74438 72801
Property/Plant/Equipment, Total - Net 9552 9449 9282 9162 8689
Property/Plant/Equipment, Total - Gross 21111 20926 20605 20212 19306
Accumulated Depreciation, Total -11559 -11477 -11323 -11050 -10617
Goodwill, Net 23277 23258 22927 22799 22284
Intangibles, Net 9282 9834 10006 10454 10850
Long Term Investments 788 799 776 766 764
Other Long Term Assets, Total 6527 6509 6426 6033 5369
Total Current Liabilities 13042 14350 14530 15489 13365
Accounts Payable 3961 4211 4167 4607 4133
Accrued Expenses 6826 6696 6856 7401 6901
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1051 2284 2285 2251 1117
Other Current Liabilities, Total 1204 1159 1222 1230 1214
Total Liabilities 34609 36180 36784 37752 37126
Total Long Term Debt 14477 14562 14615 14522 15297
Long Term Debt 14477 14562 14615 14522 15297
Minority Interest 213 230 222 219 209
Other Liabilities, Total 6877 7038 7417 7522 8255
Total Equity 37481 37174 37010 36686 35675
Common Stock 24727 24612 24488 24709 24560
Retained Earnings (Accumulated Deficit) 36920 36355 35868 35257 35115
Treasury Stock - Common -15686 -15722 -15307 -15229 -14555
Other Equity, Total -8480 -8071 -8039 -8051 -9445
Total Liabilities & Shareholders’ Equity 72090 73354 73794 74438 72801
Total Common Shares Outstanding 1736.06 1735.36 1738.95 1737.8 1743.57
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 6933 7071 4495 3687 2368
Cash From Operating Activities 9581 10533 7901 6136 6300
Cash From Operating Activities 1254 1491 1195 1078 1100
Amortization 2013 2047 2132 1936 2178
Non-Cash Items 900 695 971 766 802
Cash Taxes Paid 1864 1941 970 930 740
Cash Interest Paid 563 544 549 677 845
Changes in Working Capital -1519 -771 -892 -1331 -148
Cash From Investing Activities -1740 -2008 -2215 -1815 -1356
Capital Expenditures -1777 -1885 -2177 -1638 -1394
Other Investing Cash Flow Items, Total 37 -123 -38 -177 38
Cash From Financing Activities -7636 -5494 -2779 -4289 -10391
Financing Cash Flow Items 0 -11 0 0
Total Cash Dividends Paid -3309 -3202 -2560 -2270 -1974
Issuance (Retirement) of Stock, Net -3628 -2044 -158 -420 33
Issuance (Retirement) of Debt, Net -699 -248 -50 -1599 -8450
Foreign Exchange Effects -122 -70 71 -16 -116
Net Change in Cash 83 2961 2978 16 -5563
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 1318 6933 5900 4465 2447
Cash From Operating Activities 1143 9581 7255 4475 2065
Cash From Operating Activities 315 1254 943 626 311
Amortization 491 2013 1517 1019 512
Non-Cash Items 281 900 570 447 305
Changes in Working Capital -1262 -1519 -1675 -2082 -1510
Cash From Investing Activities -462 -1740 -1108 -624 -360
Capital Expenditures -380 -1777 -1167 -700 -321
Other Investing Cash Flow Items, Total -82 37 59 76 -39
Cash From Financing Activities -1410 -7636 -6179 -4636 -3823
Total Cash Dividends Paid -890 -3309 -2486 -1660 -832
Issuance (Retirement) of Stock, Net -478 -3628 -2984 -2243 -2248
Issuance (Retirement) of Debt, Net -42 -699 -709 -733 -743
Foreign Exchange Effects 8 -122 -173 -77 -6
Net Change in Cash -721 83 -205 -862 -2124
Financing Cash Flow Items

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Abbott Company profile

What is Abbott Laboratories?

Abbott Laboratories is a US healthcare company that employs around 99,000 people and delivers its services in over 150 countries worldwide. Abbott produces and distributes a range of products under such popular brands as PediaSure, Glucerna, Similac, Absorb and others. Its mission statement is: “To improve lives by providing cost-effective health care products and services.”

The company focuses on the following healthcare segments: Nutrition, Vascular Care, Diabetes Care, Vision, Pharmaceuticals and Diagnostics. It advocates for innovation in medicine and works to improve vision correction, take heart health treatments to the next level and introduce innovative methods of diabetes management. 

Abbott has also pioneered new ways to screen, diagnose and monitor a wide range of health conditions with greater speed and accuracy. In pharmaceuticals, the company has revolutionised packaging and delivery to meet regional needs and offer access to medicines in areas that once lacked them.

Who are the key people at Abbott Laboratories?

Miles D. White is Chairman and Chief Executive Officer of Abbott. He has held both roles since 1999, and first joined the company back in 1984. Another key figure at Abbott Laboratories is Brian Blaser, Executive Vice President, Diagnostics Products. He leads Abbott's diagnostics, molecular and point-of-care businesses. Robert Ford is Executive Vice President, Medical Devices. 

What is the modern history of Abbott Laboratories?

Abbott was incorporated in 1894, and its initial public offering took place in 1929. Among a number of landmark developments in the second half of the 20th century was the acquisition of M&R Dietetics in 1964, which made the company a leader in nutrition. Abbott’s modern diagnostics business took off in the early 1970s, and in 1985 the FDA approved the firm’s test to identify HIV in blood. In 1998 Abbott introduced Glucerna – a range of snack bars and shakes for diabetics. The first decade of the 21st century saw FDA approval of antibody drug Humira, which became the world’s leading pharmaceutical product.

What are the latest developments at Abbott Laboratories?

In January 2017 Abbott completed the acquisition of St Jude Medical – a development which put the company in a leading position in the medical devices sector. Abbott now holds the No.1 or No.2 positions in nearly every segment of the $30 billion cardiovascular market. In 2017 Abbott also recorded 40 per cent growth in its neuromodulation business, attaining the No.1 spot in spinal cord neurostimulation.

In February 2018, Abbott announced a licensing deal with mid-tech firm Surmodics Inc that could be worth up to $92 million. Under the agreement, Surmodics will exclusively license its SurVeil drug-coated balloon device to Abbott. Surmodics is testing it as a treatment for peripheral artery disease.

Since the start of 2015, the Abbott share price has ranged from a low of around $37 in February 2016 to over $60 in January 2018. The company’s market capitalisation on 2 March 2018 was $103.5 billion. Our ABT chart tracks Abbott’s recent share price movements.

Where does Abbott Laboratories operate?

Abbott is headquartered in Chicago, Illinois. It has a truly global presence, with operations across the Americas, Europe and Asia Pacific – including China, India, Japan, Australia and New Zealand.

Where is Abbott Laboratories traded?

Abbott Laboratories is listed on the New York Stock Exchange. As of 2017, the shares were mainly held by institutional investors such as BlackRock, State Street Corporation and The Vanguard Group. Check out Capital.com for the latest ABT chart.

Industry: Medical Equipment, Supplies & Distribution (NEC)

100 Abbott Park Rd
ABBOTT PARK
ILLINOIS 60064-3500
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

ETH/USD

3,094.61 Price
+0.630% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

64,728.10 Price
+1.710% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.50 Price
-0.710% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,381.44 Price
+0.140% 1D Chg, %
Long position overnight fee -0.0190%
Short position overnight fee 0.0108%
Overnight fee time 21:00 (UTC)
Spread 0.40

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading